Verana Health, which derives insights from pooled medical data, has raised 150 million.

Verana Health, a digital health business that uses big data insights to improve medical research, has secured 150 million in a series E fundraising round.

To aggregate and analyze anonymized patient data and accelerate the development of new drugs, the San Francisco-based company has formed exclusive data partnerships with a number of notable medical associations, including the American Academy of Ophthalmology, the American Academy of Neurology, and the American Urological Association. It also promises to collaborate with a slew of global pharmaceutical corporations as well as “developing biotechnology and biopharmaceutical firms.”

When artificial intelligence meets health care

Verana Health’s main products include the VeraQ platform, which is marketed as a health data engine that links fragmented, unfiltered healthcare data, and Qdata, which are data sets created from VeraQ for illnesses such as ophthalmology, neurology, and urology. Natural language processing (NLP) and machine learning are used by the Verana Health platform to “preserve the integrity of the original clinical context” of a healthcare provider’s notes and inputs — basically, making sense of unstructured text data in electronic health records (EHRs).

Launched in 2008 as DigiSight Technologies, the firm relaunched as Verana Health in 2018 in conjunction with a 30 million investment spearheaded by Alphabet’s venture capital arm GV. Verana Health claimed that with a new 150 million in the bank, it wants to double down on product development and “extend its data footprint” by forming additional partnerships with the medical and health care fraternity.

Verana Health has secured a flurry of high-profile strategic and institutional investors for its series E round, including lead backers Johnson & Johnson Innovation and Novo Growth, as well as GV, Casdin Capital, Brook Byers, the Merck Global Health Innovation Fund, THVC, and Breyer Capital.